Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 1.30B | 1.27B | 1.10B | 925.33M | 642.30M |
Gross Profit | 981.43M | 995.64M | 873.93M | 747.53M | 513.14M |
EBITDA | 271.87M | 253.46M | 445.78M | 397.59M | 133.30M |
Net Income | 222.39M | 263.24M | 325.34M | 292.47M | 216.09M |
Balance Sheet | |||||
Total Assets | 4.90B | 4.70B | 3.69B | 3.18B | 2.95B |
Cash, Cash Equivalents and Short-Term Investments | 1.18B | 1.18B | 833.79M | 1.48B | 1.14B |
Total Debt | 4.98M | 9.30M | 9.67M | 15.67M | 185.98M |
Total Liabilities | 1.42B | 1.37B | 769.05M | 653.61M | 596.06M |
Stockholders Equity | 3.49B | 3.37B | 2.90B | 2.50B | 2.34B |
Cash Flow | |||||
Free Cash Flow | 38.46M | 125.36M | 52.84M | 145.57M | 180.15M |
Operating Cash Flow | 321.46M | 418.05M | 388.32M | 488.85M | 338.53M |
Investing Cash Flow | -517.53M | -453.88M | -458.47M | -86.76M | -341.63M |
Financing Cash Flow | -116.97M | 182.71M | -215.20M | -256.38M | 674.66M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
64 Neutral | 7.83B | 35.38 | 14.86% | 1.20% | -5.18% | -9.69% | |
59 Neutral | HK$8.08B | 105.06 | 1.98% | ― | 3.42% | -70.82% | |
59 Neutral | 8.42B | 49.70 | 3.23% | 0.43% | 35.01% | 483.73% | |
51 Neutral | 3.33B | 627.27 | -2.26% | ― | -4.38% | 0.00% | |
46 Neutral | 25.31B | -19.25 | -35.47% | ― | -1.04% | 60.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
LifeTech Scientific Corporation announced its interim results for the six months ending June 30, 2025, reporting a turnover of approximately RMB676.7 million, a 3.7% increase from the previous year. However, the company’s net profit, after accounting for non-recurring items, saw a significant decrease of 73.2% compared to the same period in 2024, primarily due to changes in financial asset gains and increased share-based payment expenses.
The most recent analyst rating on (HK:1302) stock is a Buy with a HK$2.50 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.
LifeTech Scientific Corporation has announced that its Congenital Heart Defect Occluder has been admitted into the National Medical Products Administration’s Special Examination and Approval Procedure for Innovative Medical Devices. This marks the company’s 16th product to achieve such recognition, highlighting its commitment to advancing medical technology for congenital heart diseases. The occluder, designed with a full nitinol metal structure, offers a bidirectional release mechanism, enhancing treatment options for patients with patent ductus arteriosus (PDA). This development is expected to expedite the product’s registration and launch, benefiting PDA patients and expanding LifeTech’s product portfolio.
The most recent analyst rating on (HK:1302) stock is a Buy with a HK$2.50 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.
LifeTech Scientific Corporation has announced a board meeting scheduled for August 29, 2025, to discuss and approve the unaudited interim results for the first half of the year. The meeting will also consider the payment of an interim dividend and other business matters, potentially impacting the company’s financial strategy and shareholder returns.